HUMA
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 3.69 · operating margin -5272% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) $0.61 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- —
- Last synced
-
2026-08-09 12:58:10
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Jones Keith Anthony | Buy | 10,000 | $0.56 | $5,620 | Form 4 |
| 2026-08-20 | Jones Keith Anthony | Buy | 10,000 | $0.69 | $6,930 | Form 4 |
| 2026-08-17 | Jones Keith Anthony | Buy | 30,000 | $0.59 | $17,820 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-08-09
HUMA presents a critically weak financial foundation — extreme leverage, persistent negative operating margins, and an unsustainable cash burn rate that heavily discount any near-term upside.
The first sentence of the analysis written for HUMA on 2026-08-09 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -736.5% | 0.0% | 0.0% | -427.5% | -4756.8% | |
| Ebit Margin | -1451.6% | 0.0% | 0.0% | -368.4% | -1752.1% | |
| Ebitda Margin | -1091.2% | 0.0% | 0.0% | 156.2% | -1099.6% | |
| Operating Profit Margin | -5271.7% | 0.0% | 0.0% | -5404.3% | -6429.8% | |
| Pretax Profit Margin | -2003.6% | 0.0% | 0.0% | -764.5% | -2096.4% | |
| Continuous Operations Profit Margin | -2003.6% | 0.0% | 0.0% | -764.5% | -2096.4% | |
| Net Profit Margin | -2003.6% | 0.0% | 0.0% | -764.5% | -2096.4% | |
| Bottom Line Profit Margin | -2003.6% | 0.0% | 0.0% | -764.5% | -2096.4% | |
| Current Ratio | 3.690 | 2.398 | 4.515 | 7.876 | 20.755 | |
| Quick Ratio | 2.950 | 2.398 | 4.515 | 7.876 | 20.755 | |
| Solvency Ratio | -0.296 | -0.743 | -0.899 | -0.043 | -0.111 | |
| Cash Ratio | 2.749 | 2.252 | 4.362 | 7.649 | 19.683 | |
| Price To Earnings Ratio | -3.694 | -4.008 | -2.654 | -17.583 | -10.985 | |
| Price To Earnings Growth Ratio | 0.047 | -0.226 | -0.003 | 0.215 | 0.125 | |
| Forward Price To Earnings Growth Ratio | 0.047 | -0.226 | -0.003 | 0.215 | 0.125 | |
| Price To Earnings Diluted Ratio | -3.694 | -4.008 | -2.654 | -17.583 | -10.985 | |
| Price To Earnings Diluted Growth Ratio | 0.047 | -0.226 | -0.003 | 0.215 | 0.125 | |
| Price To Book Ratio | 48.862 | -11.360 | 21.683 | 1.860 | 2.372 | |
| Price To Sales Ratio | 74.540 | 0.000 | 0.000 | 138.938 | 229.442 | |
| Price To Free Cash Flow Ratio | -1.434 | -6.002 | -3.886 | -3.013 | -3.560 | |
| Price To Operating Cash Flow Ratio | -1.446 | -6.098 | -4.007 | -3.057 | -3.569 | |
| Debt To Assets Ratio | 0.557 | 0.120 | 0.448 | 0.245 | 0.179 | |
| Debt To Equity Ratio | 20.858 | -0.314 | 4.241 | 0.428 | 0.419 | |
| Debt To Capital Ratio | 0.954 | -0.458 | 0.809 | 0.300 | 0.295 | |
| Long Term Debt To Capital Ratio | 0.919 | 5.929 | 0.740 | 0.148 | 0.183 | |
| Financial Leverage Ratio | 37.429 | -2.618 | 9.466 | 1.747 | 2.345 | |
| Working Capital Turnover Ratio | 0.053 | 0.000 | 0.000 | 0.009 | 0.010 | |
| Operating Cash Flow Ratio | -5.718 | -4.917 | -3.975 | -3.633 | -7.348 | |
| Operating Cash Flow Sales Ratio | -51.542 | 0.000 | 0.000 | -45.450 | -64.283 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | 1.016 | 1.031 | 1.015 | 1.003 | |
| Debt Service Coverage Ratio | -1.977 | -14.254 | -14.617 | 0.166 | -3.194 | |
| Interest Coverage Ratio | -9.550 | -12.331 | -15.161 | -13.642 | -18.677 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -8.299 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.620 | -5.933 | -1.276 | -1.421 | -1.586 | |
| Capital Expenditure Coverage Ratio | -118.826 | -62.419 | -32.151 | -67.871 | -369.045 | |
| Dividend Paid And Capex Coverage Ratio | -118.826 | -62.419 | -32.151 | -67.871 | -369.045 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.476 | -4.310 | -2.807 | 48.152 | -8.890 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -736.5% | ▼-736.5% | ▲447.7% |
| Ebit Margin | -1451.6% | ▼-1451.6% | ▼-737.2% |
| Ebitda Margin | -1091.2% | ▼-1091.2% | ▼-684.3% |
| Operating Profit Margin | -5271.7% | ▼-5271.7% | ▼-1850.5% |
| Pretax Profit Margin | -2003.6% | ▼-2003.6% | ▼-1030.7% |
| Continuous Operations Profit Margin | -2003.6% | ▼-2003.6% | ▼-1030.7% |
| Net Profit Margin | -2003.6% | ▼-2003.6% | ▼-1030.7% |
| Bottom Line Profit Margin | -2003.6% | ▼-2003.6% | ▼-1030.7% |
| Current Ratio | 3.690 | ▲1.292 | ▼-4.157 |
| Quick Ratio | 2.950 | ▲0.552 | ▼-4.748 |
| Solvency Ratio | -0.296 | ▲0.447 | ▲0.122 |
| Cash Ratio | 2.749 | ▲0.497 | ▼-4.590 |
| Price To Earnings Ratio | -3.694 | ▲0.314 | ▲4.091 |
| Price To Earnings Growth Ratio | 0.046 | ▲0.272 | ▲0.015 |
| Forward Price To Earnings Growth Ratio | 0.046 | ▲0.272 | ▲0.015 |
| Price To Earnings Diluted Ratio | -3.694 | ▲0.314 | ▲4.091 |
| Price To Earnings Diluted Growth Ratio | 0.046 | ▲0.272 | ▲0.015 |
| Price To Book Ratio | 48.862 | ▲60.222 | ▲36.179 |
| Price To Sales Ratio | 74.540 | ▲74.540 | ▼-14.044 |
| Price To Free Cash Flow Ratio | -1.434 | ▲4.567 | ▲2.145 |
| Price To Operating Cash Flow Ratio | -1.446 | ▲4.652 | ▲2.189 |
| Debt To Assets Ratio | 0.557 | ▲0.437 | ▲0.247 |
| Debt To Equity Ratio | 20.858 | ▲21.172 | ▲15.731 |
| Debt To Capital Ratio | 0.954 | ▲1.412 | ▲0.574 |
| Long Term Debt To Capital Ratio | 0.919 | ▼-5.010 | ▼-0.665 |
| Financial Leverage Ratio | 37.429 | ▲40.047 | ▲27.755 |
| Working Capital Turnover Ratio | 0.053 | ▲0.053 | ▲0.038 |
| Operating Cash Flow Ratio | -5.718 | ▼-0.800 | ▼-0.600 |
| Operating Cash Flow Sales Ratio | -51.542 | ▼-51.542 | ▼-19.287 |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | ▼-0.008 | ▼-0.006 |
| Debt Service Coverage Ratio | -1.977 | ▲12.277 | ▲4.799 |
| Interest Coverage Ratio | -9.550 | ▲2.781 | ▲4.322 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲1.660 |
| Operating Cash Flow Coverage Ratio | -1.620 | ▲4.314 | ▲0.747 |
| Capital Expenditure Coverage Ratio | -118.826 | ▼-56.407 | ▲11.237 |
| Dividend Paid And Capex Coverage Ratio | -118.826 | ▼-56.407 | ▲11.237 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.476 | ▼-3.167 | ▼-12.410 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $151.9M | $598.3M | $293.7M | $217.4M | $289.8M | |
| Enterprise value | $166.3M | $569.9M | $270.7M | $117.7M | $123.5M | |
| EV / Sales | 81.58x | 0.00x | 0.00x | 75.23x | 97.75x | |
| EV / Op. cash flow | -1.58x | -5.81x | -3.69x | -1.66x | -1.52x | |
| EV / Free cash flow | -1.57x | -5.72x | -3.58x | -1.63x | -1.52x | |
| EV / EBITDA | -7.48x | -4.31x | -2.81x | 48.15x | -8.89x | |
| Net debt / EBITDA | -0.65x | 0.21x | 0.24x | -40.78x | 11.98x | |
| Current ratio | 3.69x | 2.40x | 4.51x | 7.88x | 20.75x | |
| Income quality | 2.57x | 0.66x | 0.66x | 5.95x | 3.07x | |
| Graham net-net | -$0 | -$1 | -$0 | $1 | $2 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 138.0% | 106.7% | 106.3% | 207.5% | 119.6% | |
| Working capital | $49.4M | $27.9M | $64.8M | $134.6M | $218.3M | |
| Invested capital | $97.1M | $66.5M | $108.9M | $184.7M | $275.5M | |
| Return on assets | -35.1% | -107.9% | -86.4% | -5.9% | -9.2% | |
| Operating ROA | -84.5% | -86.0% | -60.2% | -34.5% | -41.3% | |
| Return on tangible assets | -35.1% | -107.9% | -86.4% | -5.9% | -9.2% | |
| Return on equity | -1313.4% | 282.3% | -817.8% | -10.2% | -21.7% | |
| Return on invested capital | -107.0% | -94.7% | -89.1% | -43.2% | -29.3% | |
| Return on capital employed | -109.6% | -97.0% | -91.1% | -45.8% | -29.5% | |
| Earnings yield | -26.9% | -24.9% | -37.7% | -5.5% | -9.1% | |
| Free cash flow yield | -69.7% | -16.7% | -25.7% | -33.2% | -28.1% | |
| Capex / Op. cash flow | -0.8% | -1.6% | -3.1% | -1.5% | -0.3% | |
| Capex / Depreciation | 16.6% | 21.9% | 29.5% | 12.8% | 2.7% | |
| Capex / Sales | 43.4% | 0.0% | 0.0% | 67.0% | 17.4% | |
| SG&A / Sales | 1529.5% | 0.0% | 0.0% | 1462.2% | 1673.0% | |
| R&D / Sales | 3400.5% | 0.0% | 0.0% | 4042.2% | 4856.8% | |
| Stock comp / Sales | 478.6% | 0.0% | 0.0% | 395.1% | 803.3% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 79d | 0d | 0d | 7d | 51d | |
| Days payables outstanding | 116d | 228d | 31d | 71d | 12d | |
| Operating cycle | 370d | 0d | 0d | 7d | 51d | |
| Cash conversion cycle | 254d | -228d | -31d | -63d | 38d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-74.6%EV / Sales n/aEV / EBITDA ▼-73.5%EV / Op. cash flow ▲+4.225Earnings yield ▼-0.020
Profitability
Return on equity ▼-15.957Return on assets ▲+0.728Return on invested capital ▼-0.123Return on capital employed ▼-0.126Operating ROA ▲+0.015Income quality ▲+1.913Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-112.227Operating cycle n/aCash conversion cycle ▲+482.169Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+1.292Net debt / EBITDA ▼-0.860Working capital ▲+21518000.000Invested capital ▲+30655000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-47.6%EV / Sales ▼-16.5%EV / EBITDA ▲+15.9%EV / Op. cash flow ▼-0.062Earnings yield ▼-0.177
Profitability
Return on equity ▼-12.917Return on assets ▼-0.258Return on invested capital ▼-0.777Return on capital employed ▼-0.802Operating ROA ▼-0.432Income quality ▼-0.494Tax burden 0.000
Efficiency
Days sales outstanding ▲+28.119Days payables outstanding ▲+103.247Operating cycle ▲+319.078Cash conversion cycle ▲+215.831Capex / Sales ▲+0.260R&D / Sales ▼-14.563
Balance-sheet strength
Current ratio ▼-17.065Net debt / EBITDA ▼-12.621Working capital ▼-168867000.000Invested capital ▼-178370000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2024-03-21 | Tommy Tuberville | Buy | $15,001 - $50,000 | Filing |
| 2024-03-21 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
| 2024-03-21 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
| 2024-03-21 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
Recent news
- 2026-08-07 Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and six months ended June 30, 2026, on Wednesday, August 12, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.
- 2026-08-05 Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from its prior day''s close.
- 2026-07-28 Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts Humacyte, Inc. (HUMA) concluded the recent trading session at $0.63, signifying a -6.44% move from its prior day''s close.
- 2026-07-27 Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting – Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at multiple scientific meetings and in a recent publication – DURHAM, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that the Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of the coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting (CABG).
- 2026-07-21 Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.67, marking a +2.22% move from the previous day.
- 2026-07-20 Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights Humacyte, Inc. (HUMA) closed at $0.66 in the latest trading session, marking a -1.28% move from the prior day.
- 2026-07-14 Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous trading session.
- 2026-07-14 Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access - Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -
- 2026-06-30 Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here''s Why The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change from its previous close.
- 2026-06-25 Here''s Why Humacyte, Inc. (HUMA) Fell More Than Broader Market Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day''s close.